{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:59:03Z","timestamp":1780412343437,"version":"3.54.1"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2017,10,11]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              The proprotein convertase subtilisin\/kexin type 9 (\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9) inhibitors evolocumab and alirocumab substantially reduce low\u2010density lipoprotein cholesterol (\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              \u2010C) when added to statin therapy in patients who need additional\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              \u2010C reduction.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              We conducted a systematic review and network meta\u2010analysis of randomized trials of lipid\u2010lowering therapies from database inception through August 2016 (45\u00a0058 records retrieved). We found 69 trials of lipid\u2010lowering therapies that enrolled patients requiring further\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              \u2010C reduction while on maximally tolerated medium\u2010 or high\u2010intensity statin, of which 15 could be relevant for inclusion in\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              \u2010C reduction networks with evolocumab, alirocumab, ezetimibe, and placebo as treatment arms.\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9 inhibitors significantly reduced\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              \u2010C by 54% to 74% versus placebo and 26% to 46% versus ezetimibe. There were significant treatment differences for evolocumab 140\u00a0mg every 2\u00a0weeks at the mean of weeks 10 and 12 versus placebo (\u221274.1%; 95% credible interval \u221279.81% to \u221268.58%), alirocumab 75\u00a0mg (\u221220.03%; 95% credible interval \u221227.32% to \u221212.96%), and alirocumab 150\u00a0mg (\u221213.63%; 95% credible interval \u221222.43% to \u22125.33%) at \u226512\u00a0weeks. Treatment differences were similar in direction and magnitude for\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9 inhibitor monthly dosing. Adverse events were similar between\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9 inhibitors and control. Rates of adverse events were similar between\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9 inhibitors versus placebo or ezetimibe.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9 inhibitors added to medium\u2010 to high\u2010intensity statin therapy significantly reduce\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              \u2010C in patients requiring further\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              \u2010C reduction. The network meta\u2010analysis showed a significant treatment difference in\n              <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n              \u2010C reduction for evolocumab versus alirocumab.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.116.005367","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T00:25:18Z","timestamp":1506990318000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":74,"title":["Systematic Review and Network Meta\u2010Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia"],"prefix":"10.1161","volume":"6","author":[{"given":"Peter P.","family":"Toth","sequence":"first","affiliation":[{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University and School of Medicine, Baltimore, MD"},{"name":"CGH Medical Center, Sterling, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Worthy","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, United Kingdom"},{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravanthi R.","family":"Gandra","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"University of Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bray","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung\u2010I.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Bridges","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin M.","family":"Worth","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Dent","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Forbes","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohan","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Ross","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Kleijnen","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, United Kingdom"},{"name":"Department of Family Medicine, Maastricht University, Maastrict, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S. G.","family":"Stroes","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13985"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S102564"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.06.008"},{"key":"e_1_3_6_10_2","article-title":"LDL\u2010C goal achievement after adding or switching to ezetimibe in patients with clinical atherosclerotic cardiovascular disease or probable HeFH [in press]","author":"Aggarwal J","year":"2017","unstructured":"Aggarwal J, Patel J, Yu J, Stern K, Menzin J, Harrison DH. LDL\u2010C goal achievement after adding or switching to ezetimibe in patients with clinical atherosclerotic cardiovascular disease or probable HeFH [in press]. J Manag Care Spec Pharm. 2017.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.615"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050461"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.5559"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.001937"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv563"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2957"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.07.239"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0358-8"},{"key":"e_1_3_6_22_2","unstructured":"Sanofi\u2010Aventis US LLC . Praluent\u00ae prescribing information [Internet]. Updated April 2017. Available at: http:\/\/products.sanofi.us\/praluent\/praluent.pdf. Accessed May 23 2017."},{"key":"e_1_3_6_23_2","unstructured":"Amgen Inc . Repatha\u00ae (evolocumab) prescribing information [Internet]. Updated July 2016. Available at: http:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/repatha\/repatha_pi_hcp_english.ashx. Accessed May 23 2017."},{"key":"e_1_3_6_24_2","unstructured":"Sanofi\u2010Aventis Groupe . Praluent\u00ae summary of product characteristics [Internet]. Updated December 9 2016. Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/30956. Accessed May 23 2017."},{"key":"e_1_3_6_25_2","unstructured":"Amgen Europe B.V . Repatha\u00ae (evolocumab) summary of product characteristics [Internet]. Updated February 24 2017. Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/30628. Accessed May 23 2017."},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"e_1_3_6_27_2","volume-title":"Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care","author":"Centre for Reviews and Dissemination (CRD)","year":"2009","unstructured":"Centre for Reviews and Dissemination (CRD) . Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care [Internet]. 3rd ed. Updated January 2009. Available at: http:\/\/www.york.ac.uk\/inst\/crd\/SysRev\/!SSL!\/WebHelp\/SysRev3.htm. Accessed May 23, 2017.","edition":"3"},{"key":"e_1_3_6_28_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins JPT","year":"2011","unstructured":"Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Internet]. 2011 Updated March 2011. Available at: http:\/\/handbook.cochrane.org\/. Accessed May 23, 2017."},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4030"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316222"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-016-0724-y"},{"key":"e_1_3_6_34_2","unstructured":"Pfizer Inc . Pfizer discontinues global development of bococizumab its investigational PCSK9 inhibitor [press release]. Updated November 1 2016. Available at: http:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor. Accessed May 23 2017."},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61770-X"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-14-0130"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.10.021"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.007"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv028"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6685-y"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.03.004"},{"key":"e_1_3_6_42_2","unstructured":"Roth EM Rader D Moriarty PM Bergeron J Langslet G Baccara\u2010Dinet M Zhao J Manvelian G. A randomized phase 3 trial evaluating alirocumab every four weeks dosing as add\u2010on to statin or as monotherapy: ODYSSEY CHOICE I. Presented at IAS\u2010ISA 2015 Congress Amsterdam The Netherlands; May 16\u201023 2015."},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1520"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.11.010"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.02.011"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-16-0387"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"e_1_3_6_48_2","first-page":"2118","article-title":"Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II","volume":"130","author":"Bays H","year":"2014","unstructured":"Bays H, Farnier M, Gaudet D, Weiss R, Lima Ruiz J, Watts GF, Gouni\u2010Berthold I, Robinson JG, Jones PH, Severance R, Averna M, Steinhagen\u2010Thiessen E, Colhoun HM, Zhao J, Du Y, Hanotin C, Donahue S. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II. Circulation. 2014;130:2118.","journal-title":"Circulation"},{"key":"e_1_3_6_49_2","unstructured":"Regeneron Pharmaceuticals Inc. Sanofi . Study to evaluate the efficacy and safety of an every four weeks treatment regimen of alirocumab (REGN727\/SAR236553) in patients with primary hypercholesterolemia (ODYSSEY CHOICE 1). NCT01926782. ClinicalTrials.gov. Updated January 30 2017. Available at: http:\/\/ClinicalTrials.gov\/show\/NCT01926782. Accessed June 5 2017."},{"key":"e_1_3_6_50_2","unstructured":"Sanofi . Efficacy and safety evaluation of alirocumab in patients with heterozygous familial hypercholesterolemia or high cardiovascular risk patients with hypercholesterolemia on lipid modifying therapy. NCT02107898. ClinicalTrials.gov. Updated September 27 2016. Available at: http:\/\/clinicaltrials.gov\/show\/NCT02107898. Accessed June 5 2017."},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.11.015"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.07.028"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-305693"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.366"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"e_1_3_6_56_2","unstructured":"US Food & Drug Administration . Praluent\u00ae (alirocumab) summary review. Application number 125559Orig1s000. Updated July 24 2015. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125559Orig1s000SumR.pdf. Accessed May 23 2017."},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.08.072"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.116.005367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:50:48Z","timestamp":1715597448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.116.005367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10,11]]}},"alternative-id":["10.1161\/JAHA.116.005367"],"URL":"https:\/\/doi.org\/10.1161\/jaha.116.005367","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,11]]},"assertion":[{"value":"2016-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e005367"}}